Huei-Wen Chen

Huei-Wen Chen

Auto-generated profile, based on publicly available information

Huei-Wen Chen

Graduate Institute of Toxicology, National Taiwan University, College of Medicine, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Cancer Cell
Verified
Journal Article
Closed access
SYSung-Liang Yu
Sung-Liang Yu
HCHsuan-Yu Chen
Hsuan-Yu Chen
GCGee-Chen Chang
Gee-Chen Chang
CCChih-Yi Chen
Chih-Yi Chen
HCHuei-Wen Chen
Huei-Wen Chen
PYPan-Chyr Yang
Pan-Chyr Yang

1 July 2020 in Cell
Verified
Journal Article
Open access
Yi-Ju ChenYi-Ju Chen
Yi-Ju Chen
TRTheodoros I. Roumeliotis
Theodoros I. Roumeliotis
YCYa-Hsuan Chang
Ya-Hsuan Chang
CCChing-Tai Chen
Ching-Tai Chen
CHChia-Li Han
Chia-Li Han
Yu-Ju ChenYu-Ju Chen
Yu-Ju Chen
Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this demographically distinct disease, we performed a deep comprehensive proteogenomic study on a prospectively collected cohort in Taiwan, representing early stage, predominantly female, non-smoking lung adenocarcinoma. Integrated genomic, proteomic, and phosphoproteomic analysis delineated the demographically distinct molecular attributes and hallmarks of tumor progression. Mutational signature analysis revealed age- and gender-related mutagenesis mechanisms, characterized by high prevalence of APOBEC mutational signature in younger females and over-representation of environmental carcinogen-like mutational signatures in older females. A proteomics-informed classification distinguished the clinical characteristics of early stage patients with EGFR mutations. Furthermore, integrated protein network analysis revealed the cellular remodeling underpinning clinical trajectories and nominated candidate biomarkers for patient stratification and therapeutic intervention. This multi-omic molecular architecture may help develop strategies for management of early stage never-smoker lung adenocarcinoma.

25 March 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
WCWan-Jiun Chen
Wan-Jiun Chen
CHChao-Chi HO
Chao-Chi HO
YCYih-Leong Chang
Yih-Leong Chang
HCHsuan-Yu Chen
Hsuan-Yu Chen
CLChih-An Lin
Chih-An Lin
PYPan-Chyr Yang
Pan-Chyr Yang
Cancer stem cells (CSCs) are a promising target for treating cancer, yet how CSC plasticity is maintained in vivo is unclear and is difficult to study in vitro. Here we establish a sustainable primary culture of Oct3/4(+)/Nanog(+) lung CSCs fed with CD90(+) cancer-associated fibroblasts (CAFs) to further advance our knowledge of preserving stem cells in the tumour microenvironment. Using transcriptomics we identify the paracrine network by which CAFs enrich CSCs through de-differentiation and reacquisition of stem cell-like properties. Specifically, we find that IGF1R signalling activation in cancer cells in the presence of CAFs expressing IGF-II can induce Nanog expression and promote stemness. Moreover, this paracrine signalling predicts overall and relapse-free survival in stage I non-small cell lung cancer (NSCLC) patients. IGF-II/IGF1R signalling blockade inhibits Nanog expression and attenuates cancer stem cell features. Our data demonstrate that CAFs constitute a supporting niche for cancer stemness, and targeting this paracrine signalling may present a new therapeutic strategy for NSCLC.

24 September 2015 in Scientific Reports
Verified
Journal Article
Open access
AYAng Yuan
Ang Yuan
YHYi-Jing Hsiao
Yi-Jing Hsiao
HCHsuan-Yu Chen
Hsuan-Yu Chen
HCHuei-Wen Chen
Huei-Wen Chen
CHChao-Chi HO
Chao-Chi HO
PYPan-Chyr Yang
Pan-Chyr Yang
Macrophages in a tumor microenvironment have been characterized as M1- and M2-polarized subtypes. Here, we discovered the different macrophages’ impacts on lung cancer cell A549. The M2a/M2c subtypes promoted A549 invasion and xenograft tumor growth. The M1 subtype suppressed angiogenesis. M1 enhanced the sensitivity of A549 to cisplatin and decreased the tube formation activity and cell viability of A549 cells by inducing apoptosis and senescence. Different macrophage subtypes regulated genes involved in the immune response, cytoskeletal remodeling, coagulation, cell adhesion and apoptosis pathways in A549 cells, which was a pattern that correlated with the altered behaviors of the A549 cells. Furthermore, we found that the identified M1/M2 gene signatures were significantly correlated with the extended overall survival of lung cancer patients. These results suggest that M1/M2 gene expression signature may be used as a prognostic indicator for lung cancer patients and M1/M2 polarization may be a target of investigation of immune-modulating therapies for lung cancer in the future.

5 October 2006 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
HCHuei‐Wen Chen
Huei‐Wen Chen
SSSheng‐Fang Su
Sheng‐Fang Su
CCChiang‐Ting Chien
Chiang‐Ting Chien
WLWei‐Hsiang Lin
Wei‐Hsiang Lin
SYSung-Liang Yu
Sung-Liang Yu
PYPan‐Chyr Yang
Pan‐Chyr Yang

29 January 2008 in Nano Letters
Verified
Journal Article
Closed access
CCCheng-Chung Chou
Cheng-Chung Chou
HHHsiang-Yun Hsiao
Hsiang-Yun Hsiao
QHQi-Sheng Hong
Qi-Sheng Hong
CCChun-Houh Chen
Chun-Houh Chen
YPYa-Wen Peng
Ya-Wen Peng
‡Y‡ Pan-Chyr Yang
‡ Pan-Chyr Yang